Other news to note
Monday, July 14, 2014
Brainstorm Cell Therapeutics Inc., of New York and Petach Tikvah, Israel, said details of a preclinical study describing the safety of single and repeated intramuscular administration of Nurown, its mesenchymal stem cells, have been published in Clinical and Translational Medicine.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.